-

Secretome Therapeutics Announces Participation in Upcoming Investor Conferences

PLANO, Texas--(BUSINESS WIRE)--Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells, today announced that the company’s management team will participate in the following upcoming investor conferences through 2026.

Cantor Global Healthcare Conference
September 9–11, 2026

Oppenheimer’s Private Life Sciences Company Showcase
September 29, 2026

Stifel 2026 Virtual Cardiometabolic Forum
September 30, 2026

Leerink Partners Biopharma Private Company Connect
October 20–21, 2026

38th Annual Piper Sandler Healthcare Conference
December 1–3, 2026

About Secretome Therapeutics

Secretome Therapeutics is a clinical-stage biotechnology company based in Plano, Texas, developing novel therapies derived from neonatal cardiac progenitor cells. The Company’s lead product candidate, STM-01, is a cellular therapy designed to modulate inflammatory and fibrotic pathways and support myocardial function in Duchenne muscular dystrophy, dilated cardiomyopathy, and heart failure with preserved ejection fraction. Secretome is also advancing STM-21, a secretome-based therapeutic currently in preclinical development, and other novel nCPC-based products.

Contacts

Media Contact
Vinny Jindal
President and CEO
info@secretometx.com
https://secretometherapeutics.com/

Industry:

Secretome Therapeutics

Release Versions
English
Hashtags
#exosomes
#heartfailure
#regenerativemedicine
#secretomes
#stemcells
#therapeutics

Contacts

Media Contact
Vinny Jindal
President and CEO
info@secretometx.com
https://secretometherapeutics.com/

Social Media Profiles
NeoProgen
More News From Secretome Therapeutics

Secretome Therapeutics Expands Rare Disease Leadership Team

PLANO, Texas--(BUSINESS WIRE)--Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced the expansion of its leadership team with the appointments of Dr. Teji Singh, M.D., as Chief Medical Officer; David Chapman as Senior Vice President of Operations; Dr. Karin Lucas, Ph.D., as Vice President of Medical Affairs; and Maggie Loeffler, CPA, as Vice President of Finance & Administration. The...

Secretome Therapeutics Announces $30 Million Series A Financing From RA Capital Management to Advance STM-01 for Duchenne-Associated Cardiomyopathy

PLANO, Texas--(BUSINESS WIRE)--Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced the closing of a $30 million Series A financing from RA Capital Management, LP (“RA Capital”), a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies. RA Capital was the sole investor in the financing. The Serie...

Secretome Therapeutics Announces Participation in Upcoming Summer Investor Conferences

PLANO, Texas--(BUSINESS WIRE)--Secretome Therapeutics, a clinical-stage biotechnology company developing novel cellular and cell-based therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced that members of its management team will participate in three upcoming investor conferences this summer. Secretome is scheduled to attend the following conferences: Jefferies Global Healthcare Conference June 2 – 4, 2026 New York, New York Oppenheimer CNS & Neuro-Muscular Summi...
Back to Newsroom